{"entity":{"id":"oligoprogression","kind":"term","name":"Oligoprogression","aka":[],"tldr":"When only one or two spots grow on an otherwise working targeted therapy; treat the spots and keep the pill.","summary":"Oligoprogression describes the situation in which only one or two lesions grow while the rest of the cancer remains controlled on a targeted therapy. In ALK- and EGFR-driven non-small-cell lung cancer the usual response is local ablative treatment of the progressing lesions, with stereotactic radiotherapy or surgery, while the tyrosine kinase inhibitor continues, which extends the time a patient stays on an effective systemic therapy. It is distinct from oligometastatic disease at diagnosis, where the whole burden is limited from the start. The concept is linked from the bottlenecks on tumour heterogeneity and on metastasis biology, from the resistance-routes map, and from the idea of a test to tell true oligometastatic disease from hidden widespread spread.","asOf":"2026-09-06","links":[{"label":"Guckenberger et al., Characterisation and classification of oligometastatic disease: ESTRO and EORTC consensus (Lancet Oncology 2020)","url":"https://doi.org/10.1016/S1470-2045(19)30718-1"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["oligometastatic"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-guckenberger-lancet-oncol"],"journals":[],"dependsOn":[],"notes":[],"category":"Clinical","wikipediaChecked":"2026-09-22"},"route":"/terms/oligoprogression/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/"}],"technology":[{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"term":[{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/"}],"paper":[{"id":"paper-guckenberger-lancet-oncol","kind":"paper","name":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","route":"/key-papers/paper-guckenberger-lancet-oncol/"}],"bottleneck":[{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/"}],"idea":[{"id":"idea-bio2-oligometastatic-signature","kind":"idea","name":"A test to tell true oligometastatic disease from hidden widespread spread","route":"/ideas/idea-bio2-oligometastatic-signature/"}],"pathway":[{"id":"resistance-routes-map","kind":"pathway","name":"Resistance routes: how a blocked pathway comes back","route":"/pathways/resistance-routes-map/"}]}}